Evaluation of a B-cell leukemia-lymphoma 2- specific radiolabeled peptide nucleic acid- peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma

American Journal of Veterinary Research

Volumn 73, Issue 5, 2012, Pages 681-688

  Statham Ringen, Kimberly A ^a   Selting, Kimberly A ^a   Lattimer, Jimmy C ^a   Henry, Carolyn J ^a,b   Green, Jonathan A ^c   Bryan, Jeffrey N ^d   Jia, Fang ^a,e   Lewis, Michael R ^a,e  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PEPTIDE NUCLEIC ACID; PROTEIN BCL 2; RADIOLABELED PEPTIDE NUCLEIC ACID PEPTIDE CONJUGATE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CERVICAL LYMPH NODE; FEMALE; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; WHOLE BODY SCINTISCANNING;

ANIMALS; DOG DISEASES; DOGS; FEMALE; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; LYMPH NODES; LYMPHOCYTES; LYMPHOMA, B-CELL; MALE; PEPTIDE NUCLEIC ACIDS; PROTO-ONCOGENE PROTEINS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RNA, MESSENGER; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 84860340247     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.5.681     Document Type: Article

References (32)

1. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-1052.
2. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996;88:1046-1051.
3. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265-272.
4. Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma (Erratum published in J Clin Oncol 2010;28:4664). J Clin Oncol 2010;28:2902-2901.
5. Milner AE, Grand RJ, Vaughan AT, et al. Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation. Oncogene 1997;15:1815-1822.
6. Mirkovic N, Voehringer DW, Story MD, et al. Resistance to radiation- induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997;15:1461-1470.
7. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy- induced apoptosis in a human leukemia cell line. Blood 1993;81:151-157.
8. Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006;47:375-377.
9. Waser B, Tamma ML, Cescato R, et al. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009;50:936-941.
10. Ferone D, Resmini E, Boschetti M, et al. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders. J Endocrinol Invest 2005;28:111-117.
11. Reubi JC, Laissue J, Krenning E, et al. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27-35.
12. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
13. Villamil JA, Henry CJ, Hahn AW, et al. Hormonal and sex impact on the epidemiology of canine lymphoma [published online ahead of print Mar 14, 2010]. J Cancer Epidemiol doi:10.1155/2009/591753.
14. Rassnick KM, McEntee MC, Erb HN, et al. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med 2007;21:1364-1373.
15. Simon D, Moreno SN, Hirschberger J, et al. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a shortterm single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 2008;232:879-885.
16. Brodsky EM, Maudlin GN, Lachowicz JL, et al. Asparaginase and MOPP treatment of dogs with lymphoma. J Vet Intern Med 2009;23:578-584.
17. Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. J Vet Intern Med 1991;5:268-271.
18. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
19. Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 2001;42:377-384.
20. Tomiyasu H, Goto-Koshino Y, Takahashi M, et al. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci 2010;72:1165-1172.
21. Jia F, Figueroa SD, Gallazzi F, et al. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111Inlabeled PNA-peptide conjugates. J Nucl Med 2008;49:430-438.
22. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-441.
23. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47.
24. Nyland TG, Hager DA, Herring DS. Sonography of the liver, gallbladder, and spleen. Semin Vet Med Surg (Small Anim) 1989;4:13-31.
25. Feeney DA, Johnston GR, Hardy RM. Two-dimensional, grayscale ultrasonography for assessment of hepatic and splenic neoplasia in the dog and cat. J Am Vet Med Assoc 1984;184:68-81.
26. Wrigley RH, Konde LJ, Park RD, et al. Ultrasonographic features of splenic lymphosarcoma in dogs: 12 cases (1980-1986). J Am Vet Med Assoc 1988;193:1565-1568.
27. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
28. Lewis MR, Jia F, Gallazzi F, et al. Radiometal-labeled peptide- PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding. Bioconjug Chem 2002;13:1176-1180.
29. Lambrechts AC, Hupkes PE, Dorssers LC, et al. Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994;12:1541-1546.
30. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
31. Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999;23:127-136.
32. Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 1993;83:75-79.